Dr. Sapna Patel from MD Anderson presented early data from the Pressure-Enabled Regional Immuno-Oncology-01 (PERIO-01) clinical trial at SITC’s Tumor Microenvironment: A Holistic Approach Workshop. Early findings suggest Pressure-Enabled Drug Delivery™ enabled SD-101 (an investigational TLR9 agonist) activity within the liver metastases tumor microenvironment in metastatic uveal melanoma patients. This approach may support better immune checkpoint inhibitor performance in this patient population and other intrahepatic indications. More information on the PERIO-01 clinical trial can be found at www.periotrial.com.
